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From January to July 2017, the West Virginia Department 
of Health and Human Resources (WV DHHR) identified 
10 cases of human immunodeficiency virus (HIV) infection 
in three counties where HIV diagnoses typically range from 
six to 13 annually (1). In these counties, the spread of blood-
borne pathogens via injection drug use (IDU) is a major public 
health concern, and risk reduction programs offering syringe 
services were not available, although they were available in 
other counties (2,3). As of July 2017, nine of the 10 persons 
identified were men who have sex with men (MSM), two 
of whom had reported a prior history of IDU. Coinfections 
with syphilis (five patients), hepatitis B virus (three), and 
hepatitis C virus (HCV) (two) were also documented. By 
September 2017, the sexual or injection contacts named by 
persons in the investigation expanded the original assessment 
area to encompass 15 counties, 14 of which were among the 
nation’s top 220 counties thought to be particularly vulnerable 
to rapid spread of HIV and HCV infections via IDU (4). The 
investigated counties share some characteristics with rural Scott 
County, Indiana, where an HIV outbreak was linked to IDU in 
2015 (5), including a high prevalence of drug overdose deaths, 
prescription opioid sales, and unemployment.
WV DHHR and CDC reviewed HIV surveillance and 
partner services data to identify persons with HIV infection 
diagnosed in 2017 who resided in one of the 15 counties at the 
time of diagnosis. These included HIV-infected persons who 
were epidemiologically linked (sex or IDU partner) or molecu-
larly linked (by closely related HIV nucleotide sequences at a 
distance of ≤0.005 substitutions per site) to at least one case 
diagnosed in 2017 who resided in one of the 15 counties at 
the time of diagnosis. In addition, information on available 
health care services was obtained through individual interviews 
with 18 local providers and five persons from the investigation 
who had HIV infection.
As of October 26, 2017, the investigation had identified 
57 persons with diagnosed HIV infection, including 40 cases 
(73%) diagnosed in 2017 (Figure) and 17 cases diagnosed 
before 2017 that were epidemiologically linked (11 cases) or 
molecularly linked (six). Males accounted for 51 (89%) persons 
with HIV infection; 43 (75%) were white, and 28 (49%) were 
FIGURE. Number of HIV diagnoses per month and cumulative number of diagnoses per year — 15 West Virginia counties, 2015–2017
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aged <30 years. The mode of transmission was male-to-male 
sexual contact in 34 cases (60%), IDU in five (9%), both male-
to-male sexual contact and IDU in three (5%), heterosexual 
contact in two (4%), and unknown in 13 (23%). Ten (18%) 
persons had HIV Stage 3 (acquired immunodeficiency syn-
drome [AIDS]) at the time of diagnosis. All 40 persons with 
HIV infection diagnosed in 2017 had been linked to HIV 
care; 13 (77%) of the 17 persons diagnosed before 2017 had 
an HIV medical care visit in the past 6 months.
Risk reduction programs that provide syringe services are 
available in three of the 15 counties (none of the original 
three counties in the investigation). HIV testing is available 
at all 15 county health department clinics. HIV medical care 
providers are available in three counties (including one of the 
original counties in the investigation). Ryan White HIV/AIDS 
Program case management services, which support organiza-
tions to deliver HIV care and treatment for low-income persons 
living with HIV infection, are available throughout the state. 
Providers who offer preexposure prophylaxis for prevention of 
HIV infection are available in clinic settings in four counties 
(including two of the original counties in the investigation). 
Local providers and persons with HIV infection who were 
interviewed described stigma, transportation from remote 
areas, and poor health literacy as challenges to HIV testing 
in rural areas.
WV DHHR implemented strategies to limit further trans-
mission of HIV among the MSM population and among 
persons who inject drugs. WV DHHR is expanding access to 
HIV testing and plans to work with county health departments 
to implement additional preexposure prophylaxis clinics. For 
example, a geotargeted advertisement in the 15 counties on 
popular MSM-focused social media sites was purchased to 
encourage HIV testing. In addition, in November, WV DHHR 
selected 11 health care entities across West Virginia for funding, 
including entitites in five of the counties in this investigation, to 
support comprehensive community-level prevention programs 
that include syringe services programs where they are permit-
ted and desired. Continued efforts are underway to further 
characterize the HIV transmission network and potential HIV 
transmission through IDU risk behavior among patients and 
their extended contact networks.
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